Nonmelanoma Skin Cancer
From the Journals
Checkpoint inhibitor shows promise in advanced squamous-cell carcinoma
The PD-1 inhibitor cemiplimab has shown a response rate in about half of patients with advanced or metastatic cutaneous squamous-cell carcinoma....
From the Journals
Psoriasis therapy with biologics not linked to increased cancer risk
The international case-control study using registry data looked at risk in real-world clinical practice.
Conference Coverage
Regular skin exams reduced advanced KCs in posttransplant patients
ORLANDO - Just 2.1% of the patients in the review had annual exams, and less than half saw a dermatologist even once during an average of 5 years...
From the Journals
Keratinocyte carcinoma added no VTE risk in cohort study
With no increased risk of VTE, clinicians should more carefully consider use of prophylactic anticoagulation in patients with squamous or basal...
Conference Coverage
Spotlight on nonmelanoma skin cancer’s true burden
CHICAGO – Morbidity and mortality of nonmelanoma skin cancer are far greater than generally appreciated.
Conference Coverage
Cemiplimab impresses in advanced CSCC
CHICAGO – Investigational PD-1 checkpoint inhibitor is now under FDA review for marketing approval.
Conference Coverage
Patidegib, the first topical hedgehog inhibitor, scores in Gorlin syndrome
CHICAGO – Patidegib advances to phase 3 in patients with Gorlin syndrome and basal cell carcinomas.
Conference Coverage
Treatment of basal cell carcinoma with 1064-nm Nd:YAG laser promising
DALLAS – At the 1-year follow-up, there have been no recurrences in the 11 treated patients, as determined by clinical observation.
Conference Coverage
Novel, noninvasive skin cancer detection device shows promise
DALLAS – The investigational device is based on laser spectroscopy and machine-learning algorithms.
News
FDA begins priority review of cemiplimab for advanced cutaneous squamous cell carcinoma
Cemiplimab targets the checkpoint inhibitor PD-1.
From the Journals
HIV infection linked to higher risk of non-melanoma skin cancer
A Danish cohort study found that HIV-positive patients are more likely to develop basal cell carcinoma and squamous cell carcinoma.